Price$98.72+0.45 (+0.46%)
01:30 PM07:45 PM
News · 26 weeks79+60%
2026-04-122026-10-04
Mix3490d
- Other15(44%)
- Insider10(29%)
- SEC Filings3(9%)
- Analyst3(9%)
- Earnings2(6%)
- Dividends1(3%)
Latest news
25 items- PRAbbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoopNew powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscleEnsure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailersMuscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitnessABBOTT PARK, Ill., Oct. 7, 2026 /PRNewswire/ -- Muscle support just got simpler. Abbott (NYSE:ABT) today announced the launch of
- ANALYSTBarclays initiated coverage on Abbott Labs with a new price targetBarclays initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $120.00
- PRAbbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionFor the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF AppRising PAP can signal worsening heart failure weeks before patients experience symptomsNew capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visitsABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care
- INSIDERSEC Form 4 filed by Director Stratton John G4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Gonzalez Patricia Paola4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Conroy Kevin T4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Ahuja Nita4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Roman Michael F4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- ANALYSTAbbott Labs upgraded by Rothschild & Co Redburn with a new price targetRothschild & Co Redburn upgraded Abbott Labs from Neutral to Buy and set a new price target of $127.00
- PRAbbott hosts conference call for third-quarter earningsABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
- PRAbbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolioOnly Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligible patients get screened1-3SimpleScreen CRC expands screening options for adults age 45 and older, providing another way to help reach people who otherwise may remain unscreenedSimpleScreen CRC is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part BABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults a
- INSIDERDirector Conroy Kevin T covered exercise/tax liability with 52,507 units of Common shares without par value, decreasing direct ownership by 39% to 81,230 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic HealthPartnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviorsResearch shows registered dietitian-led medical nutrition therapy can improve glucose control and cardiometabolic health outcomes, highlighting the power of combining glucose data plus human expertise1ABBOTT PARK, Ill. and NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) and Berry Street today announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partnership brings together Lingo, Abbott's consumer biowearable that provi
- PRAbbott declares 411th consecutive quarterly dividendABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 411th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o
- PRFirst Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation CareAbbott's Volt™ Pulsed Field Ablation System is the next generation of cardiac ablation technology built on a distinctive balloon-in-basket design to treat people with heart rhythm disorders such as atrial fibrillation (AFib)The McGill University Health Centre in Montreal is the first in Canada to use the system to treat its patients with AFibPulsed field ablation (PFA) is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythmsMISSISSAUGA, ON, Sept. 15, 2026 /CNW/ -- Abbott (NYSE:ABT) today announced that its Volt™ Pulsed Field Ablation System, designed to deliver more precise, targeted energy with fewer catheter e
- PRAbbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recallSettlement does not represent any finding of fault or liabilityAs the government has previously indicated, it has closed its criminal investigation on this matterTests by government regulators of unopened product from the homes of the infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakiiNo unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii ABBOTT PARK, Ill., Sept. 14, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorn
- PRAbbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythmsAbbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) casesStrong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patientsFDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin AmericaABBOTT PARK, Ill., Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™
- INSIDERVICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDEREVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formulaNew Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milkAbbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formulaProduct is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailersABBOTT PARK, Ill., Aug. 31, 2026 /PRNewswire/ -- Parents looking for an i
- INSIDERCHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of strokeAmulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medicationAmulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a strokeRecent clinical trial data show Amulet 360 met benchmarks for safety and effectivenessABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart
- PRAbbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetesLibre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetesDesigned to seamlessly address a critical gap in ketone monitoring, providing needed health data without adding burden on people living with diabetesIntegrates with the latest-generation Libre app available in the U.S. and the full Libre digital health ecosystem; designed for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, today announced U.S. Food and
- SECAbbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infantsAgreements will resolve the Gill case and claims involving approximately 2,000 other individualsAbbott and the medical community stand by the safety of preterm infant formulasRegulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evidence that they cause necrotizing enterocolitisABBOTT PARK, Ill., Aug. 20, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants. In July 2024, a St. Louis jury awarded the plaintiff in the Gill case $495 million in d
ABT FAQ
7 questionsWhat does Abbott Laboratories do?
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...Where does ABT stock trade?
Abbott Laboratories (ABT) is listed on NYSE.What sector and industry is ABT in?
Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does ABT pay a dividend?
Yes. ABT's next ex-dividend date is 2026-10-15 with a declared cash dividend of $0.63 per share, payable 2026-11-16.What are analysts saying about ABT?
Abbott Laboratories has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-10-07.What companies are similar to ABT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABT side-by-side with any of them on Quantisnow.How can I track ABT on Quantisnow?
Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.